Drugs / REM-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05374915 | Feb 2024 → Dec 2025 overdue | breast carcinoma | Kintara Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05374915 ↗ |
| Route | Intravenous | “Infusion of REM-001 (iv)” NCT05374915 ↗ |